Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	724.67	571.39	749.08	399.96	591.88	69.71
Trading Asset Securities	10	208	-	43.01	87.13	80
Cash & Short-Term Investments	734.67	779.39	749.08	442.98	679.01	149.71
Cash Growth	-1.28%	4.05%	69.10%	-34.76%	353.54%	157.70%
Accounts Receivable	554.02	539.21	297.26	251.29	143.37	109.12
Other Receivables	8.02	7.92	3.27	1.19	1.05	5.05
Receivables	562.03	547.13	300.53	252.48	144.41	114.17
Inventory	621.52	584.04	377.17	323.48	250.82	185
Other Current Assets	79.84	94.97	67.98	33.53	29.86	39.03
Total Current Assets	1,998	2,006	1,495	1,052	1,104	487.91
Property, Plant & Equipment	2,221	1,892	1,405	988.47	706.55	613.74
Long-Term Investments	245.04	215.04	117.5	94.5	-	-
Goodwill	156.34	156.34	156.34	156.34	160.92	162.2
Other Intangible Assets	106.05	108.19	112.1	98.18	88.57	87.11
Long-Term Deferred Tax Assets	95.93	88.27	46.65	28.13	16.63	26.5
Long-Term Deferred Charges	246.67	203.2	41.03	38.77	15.66	12.02
Other Long-Term Assets	369.69	409.4	173.84	65.44	34.46	6.11
Total Assets	5,439	5,078	3,547	2,522	2,127	1,396
Accounts Payable	502.96	393.45	141.93	87.61	72.36	24.49
Accrued Expenses	44.92	75.02	86.14	48.49	43.99	32.98
Short-Term Debt	1,084	1,044	546.02	318.73	77.27	177.95
Current Portion of Long-Term Debt	161.02	127.68	40.08	-	-	32
Current Portion of Leases	-	-	5.29	1.47	3.64	-
Current Income Taxes Payable	40.3	24.32	11.47	5.37	-	12.85
Current Unearned Revenue	19.36	61.21	8.39	6.85	26.17	13.34
Other Current Liabilities	29.42	27.21	134.01	82.8	51.96	88.6
Total Current Liabilities	1,882	1,753	973.34	551.32	275.4	382.21
Long-Term Debt	513.82	445.21	286.49	-	-	37.95
Long-Term Leases	43.37	25.75	17.18	-	2.74	-
Long-Term Unearned Revenue	60.24	55.99	31.46	35.32	21.74	4.4
Long-Term Deferred Tax Liabilities	8.39	8.61	10.16	10.77	4.26	4.99
Other Long-Term Liabilities	95.64	107.43	39.31	-	14	-
Total Liabilities	2,603	2,396	1,358	597.41	318.14	429.55
Common Stock	219.78	219.78	213.18	213.18	213.18	159.89
Additional Paid-In Capital	1,603	1,598	1,341	1,319	1,318	641.03
Retained Earnings	945.13	792.51	495.37	374.95	277.82	162.43
Comprehensive Income & Other	50.78	50.11	120.23	3.33	2.2	-
Total Common Equity	2,818	2,660	2,170	1,910	1,811	963.34
Minority Interest	17.6	21.95	19.04	14.66	-2.61	2.68
Shareholders' Equity	2,836	2,682	2,189	1,925	1,809	966.02
Total Liabilities & Equity	5,439	5,078	3,547	2,522	2,127	1,396
Total Debt	1,802	1,642	895.07	320.19	83.65	247.89
Net Cash (Debt)	-1,067	-863.06	-145.98	122.79	595.36	-98.18
Net Cash Growth	-	-	-	-79.38%	-	-
Net Cash Per Share	-4.91	-3.93	-0.68	0.58	3.10	-0.61
Filing Date Shares Outstanding	219.78	219.78	213.18	213.18	213.18	159.89
Total Common Shares Outstanding	219.78	219.78	213.18	213.18	213.18	159.89
Working Capital	116.44	252.82	521.43	501.15	828.71	105.7
Book Value Per Share	12.82	12.10	10.18	8.96	8.50	6.03
Tangible Book Value	2,556	2,396	1,902	1,656	1,562	714.04
Tangible Book Value Per Share	11.63	10.90	8.92	7.77	7.33	4.47
Buildings	-	-	504.29	476.24	376.08	339.12
Machinery	-	-	1,123	652.13	529	435.18
Construction In Progress	-	-	185.96	180.11	34.85	9.88

Source: S&P Global Market Intelligence. Standard template. Financial Sources.